Document is current
Any future updates will be listed below
-
Authors
Miao, Diana https://orcid.org/0000-0003-1754-2319
Margolis, Claire A. https://orcid.org/0000-0002-1019-2419
Vokes, Natalie I.
Liu, David
Taylor-Weiner, Amaro
Wankowicz, Stephanie M.
Adeegbe, Dennis
Keliher, Daniel https://orcid.org/0000-0001-5144-7898
Schilling, Bastian https://orcid.org/0000-0001-8859-4103
Tracy, Adam
Manos, Michael
Chau, Nicole G.
Hanna, Glenn J.
Polak, Paz https://orcid.org/0000-0002-2153-4488
Rodig, Scott J.
Signoretti, Sabina
Sholl, Lynette M.
Engelman, Jeffrey A.
Getz, Gad https://orcid.org/0000-0002-0936-0753
Jänne, Pasi A.
Haddad, Robert I.
Choueiri, Toni K.
Barbie, David A.
Haq, Rizwan
Awad, Mark M.
Schadendorf, Dirk
Hodi, F. Stephen
Bellmunt, Joaquim
Wong, Kwok-Kin
Hammerman, Peter
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
- License Information
-
More Information
Article History
Received: 23 August 2017
Accepted: 14 May 2018
First Online: 27 August 2018
Competing interests
: A.T., D.L., D.M., M.M., N.I.V., C.A.M., D.A., D.K., S.M.W., L.M.S., A.T.-W., P.P., K.-K.W., S.J.R., J.B., P.A.J., N.G.C., R.H., and M.M.A. declare no conflicts of interest. T.K.C. has advisory roles with AstraZeneca, Bayer, Bristol-Myers Squibb, Cerulean, Elsa, Foundation Medicine, Genentech, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, and Elsai. T.K.C. receives research funding from AstraZeneca, Bristol-Myers Squibb, Exelixis, Genentech, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Roche, Tracon, and Eisai. G.J.H. receives institutional support from Bristol-Myers Squibb and EMD Serono. B.S. is on the advisory board or has received honoraria from Novartis, Roche, Bristol-Myers Squibb, and MSD Sharp & Dohme, research funding from Bristol-Myers Squibb and MSD Sharp & Dohme, and travel support from Novartis, Roche, Bristol-Myers Squibb, and Amgen. R.I.H. has advisory roles with Bristol-Myers Squibb, Pfizer, Merck, AstraZeneca, Genentech, and Celgene. R.I.H. receives research funding from Bristol-Myers Squibb, Merck, Genentech, and Pfizer. S.S. is a consultant for AstraZeneca and Merck and receives research funding from AstraZeneca, Bristol-Myers Squibb, Exelixis, and Roche. G.G. has an advisory role with MD Anderson and receives research funding from IBM and Bayer. G.G. is listed as an inventor on patent applications regarding MuTect, ABSOLUTE, and Polysolver. D.A.B. is a consultant for N of One. D.S. receives consulting fees from Amgen, GlaxoSmithKline, BMS, Novartis, Roche, Amgen, Merck, AstraZeneca, Merck-Serono, and Pfizer. P.H. and J.A.E. are employees of Novartis. F.S.H. is a consultant to Bristol-Myers Squibb, Merck, Novartis, EMD Serono, Sanofi, and Genentech and receives institutional research support from Bristol-Myers Squibb. E.M.V.A. holds consulting roles with Tango Therapeutics, Invitae, and Genome Medical and receives research support from Bristol-Myers Squibb and Novartis.
